Mattingly Gregory W, Anderson Richard H
1Washington University School of Medicine,Department of Psychiatry and Behavioral Neurosciences,St. Charles,Missouri,USA.
2Midwest Research Group,St. Charles,Missouri,USA.
CNS Spectr. 2016 Dec;21(S1):45-59. doi: 10.1017/S1092852916000808.
Our knowledge and understanding of the underlying neurobiology and symptomatic expression of ADHD has advanced dramatically over the past decade. Associated with these advances has been a similar explosion of new treatment options to individualize treatment for our patients. This article will: ∙ review strategies to measure ADHD symptoms and functional difficulties while seeking to achieve full symptomatic remission throughout the day ∙ summarize recent findings regarding the management and prioritization of ADHD and comorbid conditions and ∙ discuss the various pharmacologic treatment options with a focus on recently developed molecules and novel delivery systems.
在过去十年中,我们对注意力缺陷多动障碍(ADHD)潜在神经生物学及症状表现的认识和理解有了显著进展。与这些进展相伴的是,针对我们患者的个体化治疗,新的治疗选择也呈类似的爆发式增长。本文将:∙ 回顾在力求全天实现症状完全缓解的同时测量ADHD症状及功能障碍的策略 ∙ 总结关于ADHD及共病管理和优先级排序的最新研究发现 ∙ 并讨论各种药物治疗选择,重点关注最近研发的分子和新型给药系统。